ZTE
ZTE, a leading global mobile device maker, today began to showcase a range of smart devices at Mobile World Congress 2015 that are soon to be launched in markets across Europe. Flagship products on show include the smart voice ZTE Star 2, Smart Sense ZTE Blade S6, and the innovative Spro 2, the only smart projector with a touchscreen Android operating system.
“We are very excited to confirm the upcoming European availability for several of our hottest new products,” said Kan Yulun, CEO of EMEA & LATAM, ZTE Mobile Devices, and Vice President of ZTE Corporation. “We will continue to bring our latest smartphones to markets across Europe, as well as other smart connected devices such as our Spro 2 smart projector.”
With optimized system-level voice control, the ZTE Star 2 on show at MWC 2015 has been upgraded to feature English-language GPS and speech-to-text input that supports British English. ZTE’s Star 2 is set to launch in Germany at CeBIT on 12 March 2015. At present, voice control functions that support Spanish are under development, which will be the third smart voice language available after Chinese and English.
The ZTE Blade S6, which features ZTE’s innovative Smart Sense - an intuitive and practical set of gesture and motion controls - will soon be launched offline via channel partners in Germany, Spain, and France at the end of the month. This follows recent online launches via AliExpress globally, as well as via eBay and Amazon for the United Kingdom, Germany, France, Italy and Spain. Outside Europe, the ZTE Blade S6 is also set for offline launches in Malaysia, Thailand, Russia and other markets across the Asia Pacific. The ZTE Blade L3 was also on display at ZTE’s booth, a device aimed at the budget shopper and younger smartphone user, which is also destined for European launches in April 2015. Devices in the Blade series underscore ZTE’s commitment to offering premium smartphones at affordable prices.
Unlike any other smart projector, the Spro 2 features a touchscreen Android operating system that provides full access to the Google Play store and a mobile hotspot. The smart projector was revealed at the 2015 Consumer Electronics Show and received four prestigious awards. The Spro 2 will be available later this year in the United States through wireless carriers and across European markets.
ZTE’s MWC 2015 smartphone line-up also included the iF DESIGN AWARD 2015 winner, ZTE Grand S3 with Eyeprint ID, as well as the ZTE Open L – one of the first LTE smartphones to ship with the latest version of Firefox OS 2.2. In addition to smartphones, other technology on display included the ZTE Sports Camera and ZTE in-house LTE chipsets.
About ZTE Mobile Devices
ZTE Mobile Devices is a division of ZTE Corporation, a global telecommunications equipment, networks and mobile devices company headquartered in Shenzhen, China. ZTE is a publicly traded company listed on the Hong Kong and Shenzhen stock exchanges.
ZTE is one of the global leaders in the mobile handset manufacturing industry in the world, offering a complete range of mobile devices, including mobile phones, tablets, mobile broadband modems and hotspots and family desktop integration terminals.
ZTE has strategic partnerships with 47 of the world’s top 50 carriers. Additionally, ZTE ranked No.1 in PCT patent applications according to the WIPO (World Intellectual Property Organization) in 2011 and 2012. For more information, please visit: www.ztedevice.com
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150301005211/en/
Contact:
Media Contacts:
ZTE Corporation
Eva Chen, +86 21
68897511
chen.zhengying@zte.com.cn
or
Waggener
Edstrom Communications
Laura Liu, +86 10 59001242
laural@waggeneredstrom.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release
DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum